OBJECTIVE

The purpose of this article is to review the decade-long experience with imatinib and other molecular targeted agents in the treatment of gastrointestinal stromal tumor (GIST).

CONCLUSION

Tremendous progress has been made in the medical management of GIST since the inception of imatinib, and imaging has played a key role in understanding the typical and atypical responses of GIST to molecular targeted therapies.